Hualan Biological Bacterin Inc. (301207.SZ)

CNY 18.51

(0.16%)

Market Cap (In CNY)

11.08 Billion

Revenue (In CNY)

2.41 Billion

Net Income (In CNY)

859.96 Million

Avg. Volume

2.99 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
15.42-28.25
PE
-
EPS
-
Beta Value
0.815
ISIN
CNE1000058J9
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Wenjue An
Employee Count
-
Website
https://www.hualanbacterin.com
Ipo Date
2022-02-18
Details
Hualan Biological Bacterin Inc. engages in the research, development, production, and sale of vaccines in China. It offers It offers influenza virus split vaccines, quadrivalent influenza virus split vaccines, H1N1 influenza virus split vaccines, ACYW135 meningococcal polysaccharide plague vaccines, recombinant hepatitis B vaccines, and group A and C meningococcal polysaccharide vaccines, as well as genetic engineering vaccines for human use. The company was founded in 2005 and is based in Xinxiang, China. Hualan Biological Bacterin Inc. was formerly a subsidiary of Hualan Biological Engineering Inc.

More Stocks